| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Delanaye P et al. | Paricalcitol for reduction of albuminuria in diabetes. | 2011 | Lancet | pmid:21334526 |
| He W et al. | Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. | 2011 | J. Am. Soc. Nephrol. | pmid:21030600 |
| Becker LE et al. | Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. | 2011 | Am. J. Physiol. Renal Physiol. | pmid:21159735 |
| Bae S et al. | Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. | 2011 | Cardiovasc. Res. | pmid:21565836 |
| Schumock GT et al. | Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. | 2011 | Nephron Clin Pract | pmid:20699620 |
| Kim TH and Ji JD | Paricalcitol, a synthetic vitamin D analog: a candidate for combination therapy with biological agents in rheumatoid arthritis. | 2010 | Med. Hypotheses | pmid:20736134 |
| Park JW et al. | Paricalcitol attenuates cyclosporine-induced kidney injury in rats. | 2010 | Kidney Int. | pmid:20237458 |
| Cannata-AndÃa JB et al. | New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. | 2010 | Pediatr. Nephrol. | pmid:20151157 |
| Shalhoub V et al. | Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. | 2010 | J. Cell. Biochem. | pmid:20665672 |
| Vargemezis V et al. | Pivotal role of paricalcitol in the treatment of calcific uremic arteriolopathy in the presence of a parathyroid adenoma. | 2010 | Am. J. Kidney Dis. | pmid:19481317 |
| Kong J et al. | Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. | 2010 | Am. J. Pathol. | pmid:20616348 |
| Eleftheriadis T et al. | Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-alpha and IL-8 production by human peripheral blood mononuclear cells. | 2010 | Int Urol Nephrol | pmid:19259778 |
| Agarwal R | Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects? | 2010 | Kidney Int. | pmid:20467430 |
| Nuijten M et al. | Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. | 2010 | Clin Drug Investig | pmid:20586517 |
| de Zeeuw D et al. | Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. | 2010 | Lancet | pmid:21055801 |
| Thomas MC and Cooper ME | Into the light? Diabetic nephropathy and vitamin D. | 2010 | Lancet | pmid:21055802 |
| Wollina U | [Cutaneous calciphylaxis]. | 2010 | Hautarzt | pmid:21103856 |
| Matias PJ et al. | Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. | 2010 | Clin J Am Soc Nephrol | pmid:20203163 |
| Pérez V et al. | Effect of paricalcitol on the urinary peptidome of kidney transplant patients. | 2010 | Transplant. Proc. | pmid:20970572 |
| Park JW et al. | Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. | 2010 | Am. J. Physiol. Renal Physiol. | pmid:19940033 |
| Gotch F et al. | Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. | 2010 | Blood Purif. | pmid:20093823 |
| Schneider R et al. | An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. | 2010 | Surgery | pmid:21134538 |
| Lund RJ et al. | Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients. | 2010 | Am. J. Nephrol. | pmid:20016142 |
| Miller JE et al. | Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients. | 2010 | Am. J. Nephrol. | pmid:20814200 |
| Deb DK et al. | Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. | 2010 | Kidney Int. | pmid:20182412 |
| Kalantar-Zadeh K et al. | Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. | 2010 | Kidney Int. Suppl. | pmid:20671739 |
| Goltzman D | Do calcimimetics directly alter bone remodeling? | 2010 | Am. J. Physiol. Renal Physiol. | pmid:20237238 |
| Li X et al. | Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. | 2010 | Arterioscler. Thromb. Vasc. Biol. | pmid:19948844 |
| Mizobuchi M et al. | Myocardial effects of VDR activators in renal failure. | 2010 | J. Steroid Biochem. Mol. Biol. | pmid:20236614 |
| Manenti L et al. | Increased fetuin-A levels following treatment with a vitamin D analog. | 2010 | Kidney Int. | pmid:21076451 |
| Finch JL et al. | Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. | 2010 | Am. J. Physiol. Renal Physiol. | pmid:20200094 |
| Reis FN | The unsolved cyclosporine-induced kidney injury: is paricalcitol a feasible new renoprotective option? | 2010 | Kidney Int. | pmid:20508662 |
| Husain K et al. | Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. | 2010 | Am. J. Nephrol. | pmid:20720404 |
| Achinger SG et al. | Use of 3-hour daily hemodialysis and paricalcitol in patients with severe secondary hyperparathyroidism: A case series. | 2010 | Hemodial Int | pmid:20337743 |
| Müller D and Müller DN | Battle against the renin-angiotensin system: help from an unexpected party. | 2009 | Nephrol. Dial. Transplant. | pmid:19176687 |
| Sochorová K et al. | Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. | 2009 | Clin. Immunol. | pmid:19660988 |
| Abdul Gafor AH et al. | Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism. | 2009 | Nephrology (Carlton) | pmid:19298641 |
| Hansen D et al. | Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. | 2009 | BMC Nephrol | pmid:19778452 |
| Patel TV and Singh AK | Role of vitamin D in chronic kidney disease. | 2009 | Semin. Nephrol. | pmid:19371802 |
| Lambers Heerspink HJ et al. | The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. | 2009 | Am. J. Nephrol. | pmid:19521070 |
| Li M and Batuman V | Vitamin D: a new hope for chronic kidney disease? | 2009 | Kidney Int. | pmid:19946310 |
| Fishbane S et al. | Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. | 2009 | Am. J. Kidney Dis. | pmid:19596163 |
| Nuijten M et al. | Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. | 2009 | Curr Med Res Opin | pmid:19335321 |
| Cozzolino M et al. | Importance of vitamin D receptor activation in clinical practice. | 2009 | Contrib Nephrol | pmid:19494616 |
| Brancaccio D et al. | New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. | 2009 | Contrib Nephrol | pmid:19494617 |
| Eleftheriadis T et al. | The effect of paricalcitol on osteoprotegerin production by human peripheral blood mononuclear cells. | 2009 | J. Rheumatol. | pmid:19342729 |
| Sonikian M et al. | Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use? | 2009 | Blood Purif. | pmid:19141997 |
| Tan X et al. | Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. | 2009 | Kidney Int. | pmid:19759524 |
| Mazzaferro S et al. | Vitamin D receptor activators. | 2009 | Int J Artif Organs | pmid:19363782 |
| Husain K et al. | Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. | 2009 | Am. J. Nephrol. | pmid:19033720 |
Paricalcitol
Paricalcitol is a lipid of Sterol Lipids (ST) class. Paricalcitol is associated with abnormalities such as Vitamin D Deficiency. The involved functions are known as Hypertrophy, Left Ventricular. Paricalcitol often locates in Blood.
Cross Reference
Introduction
To understand associated biological information of Paricalcitol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Paricalcitol?
Paricalcitol is suspected in Vitamin D Deficiency and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
No disease MeSH terms mapped to the current reference collection.
PubChem Associated disorders and diseases
What pathways are associated with Paricalcitol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Paricalcitol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Paricalcitol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What genes are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.
What common seen animal models are associated with Paricalcitol?
There are no associated biomedical information in the current reference collection.